German pharmaceutical giant Bayer said it expects to spend $3.4 million to expand its Indonesian production capacity for effervescents this year.
As Bayer moves closer to hiving off its plastics businesses and becoming a life sciences-focused company, a restructuring is afoot, the company said Wednesday. But it's one that won't cost the drugmaker any staff positions.
England's Cancer Drugs Fund has drawn a hard line when it comes to its list of covered meds, axing cancer treatments despite pushback from drugmakers. But Bayer scored a victory for its cancer med Stivarga, getting the fund to reverse its decision and keep the drug on its list even as rival companies lose similar battles.
China's Sinocare reportedly has made a $1 billion bid for Germany-based Bayer's diabetes devices. As maker of blood-sugar monitors, Sinocare would be challenging a broader based company, Panasonic Healthcare, already months into discussions with the seller.
Chinese bidders are emerging in the long-sought sale of Bayer's diabetes device business, as the German giant seeks to focus on its core pharmaceutical interests.
Johnson & Johnson and Bayer are wont to brag about their achievements with Xarelto, one of the new generation of anticoagulant meds. Rightfully so: Though second to that market by many months, the companies grabbed market share from their old standby rival warfarin and their head-to-head competition Pradaxa, too.
Australia's Sirtex may be on the radar of Bayer AG as the two companies focus on radiation treatments for liver cancers and see Singapore as a key regional location for clinical and sales efforts in regional oncology.
When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.
Bayer HealthCare's whistle-blowing sales rep finally got a job offer at his old company. Thing is, that offer was 500 miles away from home--and a U.S. judge was none too impressed with the gambit.
Debiotech has gained an option with Oregon-based iSense CGM to acquire exclusive rights to use its continuous glucose monitoring technology with patch insulin pumps for diabetes treatment. The companies expect that the integration of Debiotech's Jewel Pump with the iSense continuous glucose monitor technology could lead to the creation of an accurate artificial pancreas--a device that continuously measures insulin levels and then automatically dispenses insulin accordingly in response.